Oncotarget

Research Papers:

Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation

Yamato Tanabe, Soichiro Sasaki, Naofumi Mukaida and Tomohisa Baba _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:48335-48345. https://doi.org/10.18632/oncotarget.10227

Metrics: PDF 1840 views  |   HTML 2538 views  |   ?  


Abstract

Yamato Tanabe1, Soichiro Sasaki1, Naofumi Mukaida1, Tomohisa Baba1

1Division of Molecular Bioregulation, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

Correspondence to:

Tomohisa Baba, email: [email protected]

Keywords: colorectal cancer, CCL3, CCR5, cancer-associated fibroblast, maraviroc

Received: January 26, 2016    Accepted: June 07, 2016    Published: June 22, 2016

ABSTRACT

We previously demonstrated that cancer-associated fibroblasts (CAFs) accumulate at tumor sites through the interaction between a chemokine, CCL3, and its receptor, CCR5, in the late phase of colitis-associated colon carcinogenesis. Here we examined the effect of a CCR5 antagonist, maraviroc, on tumor growth arising from the orthotopic injection of mouse or human colon cancer cell lines into the cecal wall by focusing on CAFs. Orthotopic injection of either cell line caused tumor formation together with leukocyte infiltration and fibroblast accumulation. Concomitant oral administration of maraviroc reduced tumor formation with few effects on leukocyte infiltration. In contrast, maraviroc reduced the intratumor number of α-smooth muscle actin-positive fibroblasts, which express epidermal growth factor, a crucial growth factor for colon cancer cell growth. These observations suggest that maraviroc or other CCR5 antagonists might act as novel anti-CRC drugs to dampen CAFs, an essential cell component for tumor progression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10227